Project description
Novel, affordable genome-sequencing kit could support universal use
Using Sanger sequencing for the entire human genome for the first time took 13 years and cost about USD 3 billion. Recently, high-throughput next-generation sequencing (NGS) technology has made it possible to sequence a person's entire genome in a few hours for about USD 1 000. NGS is increasingly utilised in oncology: tumour analysis reveals clinical biomarkers for diagnosis, prognosis and assessment of progression as well as for personalised medicine. However, despite the significant reduction in costs and advances in technology, both must be accelerated to enable access to the best by all patients. The EU-funded oncNGS project is developing an NGS tumour-marker analysis kit applicable to all tumour types that will include automated data analysis, interpretation and reporting to support decision-making. Standard use of NGS for tumour analysis could soon significantly enhance outcomes.
Objective
oncNGS consortium challenges the market to research and develop novel affordable solutions to provide the best NGS tests, for all solid tumours / lymphomas patients.
The challenge will consist in providing: (1) efficient molecular DNA/RNA profiling of tumour-derived material in liquid biopsies by means of (2) pan-cancer tumour marker analysis kit including NGS analysis integrated with (3) an ICT decision support system including analytical test interpretation and reporting.
Thanks to the provided solutions, oncNGS consortium will be able to address their common identified unmet medical needs: (1) Establishment of valuable common tumour profiling strategy allowing to provide equal access to innovative medicines to all; (2) Outcome research analysis after treatments with targeted therapies as diverse testing leads to lowering the pooling capacity of obtained results, needed to obtain large enough sample numbers to perform statistics analyses; (3) Application of such essential testing to all patients, breaking down current unacceptable inequities due to the high costs of current diagnostics tests.
oncNGS is a strong consortium composed by eight buyers from five member states (SC and IJB from Belgium, IC and HCL from France, HC and LMU from Germany, ACC from Italy and ICO from Spain) supported by six entities with wide experience in their fields (AQuAS from Spain is expert in precommercial procurement, BCR from Belgium and INCa from France are experts in cancer control, IBSAL and VHIO are experienced in biomedical research in the field of haematologic malignancies and DCP is experts in intellectual property rights and freedom to operate analysis)
oncNGS consortium will challenge the market launching a pre-commercial procurement procedure, a competitive process enabling the buyers to compare the developments carried out by the contracted suppliers through three phases: solution design, prototyping and clinical validation of a limited set of R&D supplies.
Fields of science
Programme(s)
Topic(s)
Funding Scheme
PCP - Pre-Commercial ProcurementCoordinator
1050 Elsene
Belgium
See on map
Participants (17)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
9000 Gent
See on map
00144 Roma
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
20121 Milano
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
00168 Roma
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
00144 Roma
See on map
75231 Paris
See on map
08908 L'HOSPITALET DEL LLOBREGAT
See on map
1070 Anderlecht
See on map
80539 MUNCHEN
See on map
10117 Berlin
See on map
69002 Lyon
See on map
08005 Barcelona
See on map
9830 Sint-Martens-Latem
See on map
1210 Bruxelles / Brussel
See on map
92513 Boulogne Billancourt
See on map
42002 Soria
See on map
08035 Barcelona
See on map